Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis

Aim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. High cost of such treatment and risk of adverse events related to it requires definition of strict indicati...

Full description

Saved in:
Bibliographic Details
Main Authors: A. O. Golovenko, I. L. Khalif, O. V. Golovenko, V. V. Veselov
Format: Article
Language:Russian
Published: Gastro LLC 2013-10-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/1233
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860217197101056
author A. O. Golovenko
I. L. Khalif
O. V. Golovenko
V. V. Veselov
author_facet A. O. Golovenko
I. L. Khalif
O. V. Golovenko
V. V. Veselov
author_sort A. O. Golovenko
collection DOAJ
description Aim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. High cost of such treatment and risk of adverse events related to it requires definition of strict indications for application of this drug. It was necessary to detect factors due to which at early stage of biological therapy it is possible to decide whether infliximab will allow to achieve long-term clinical remission, and also to avoid operative treatment.Material and methods. The retrospective analysis of biological therapy results in 30 patients with severe steroid-resistant attack of ulcerative colitis, assessed by Truelove and Witts’ criteria was carried out.Results. Colectomy due to inefficiency of infliximab was executed in 11 patients (36,7%). In groups of the patients, who undergone surgery and those, who avoided resection of the large intestine, various clinical, laboratory and endoscopic parameters were compared. By results of logistic regression predictors of infliximab inefficiency were determined: presence of extensive ulcerative mucosal defects of the colon prior to the beginning of biological therapy (accuracy of colectomy prognosis 78%) and absence of clinical remission at the third injection of the drug (accuracy of colectomy prognosis of 69%).Conclusions. The investigated risk factors do not allow clear-cut prediction of relapse-free course of ulcerative colitis for one year of maintenance therapy by infliximab.
format Article
id doaj-art-9ebd9e00ffa74f498e3da128f2f27c7e
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2013-10-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-9ebd9e00ffa74f498e3da128f2f27c7e2025-02-10T16:14:33ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732013-10-012356573820Predictors of infliximab efficacy in patients with severe attack of ulcerative colitisA. O. Golovenko0I. L. Khalif1O. V. Golovenko2V. V. Veselov3Federal state-funded institution «State Scientific Center of Coloproctology» Ministry of heathcare of the Russian FederationFederal state-funded institution «State Scientific Center of Coloproctology» Ministry of heathcare of the Russian FederationFederal state-funded institution «State Scientific Center of Coloproctology» Ministry of heathcare of the Russian FederationFederal state-funded institution «State Scientific Center of Coloproctology» Ministry of heathcare of the Russian FederationAim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. High cost of such treatment and risk of adverse events related to it requires definition of strict indications for application of this drug. It was necessary to detect factors due to which at early stage of biological therapy it is possible to decide whether infliximab will allow to achieve long-term clinical remission, and also to avoid operative treatment.Material and methods. The retrospective analysis of biological therapy results in 30 patients with severe steroid-resistant attack of ulcerative colitis, assessed by Truelove and Witts’ criteria was carried out.Results. Colectomy due to inefficiency of infliximab was executed in 11 patients (36,7%). In groups of the patients, who undergone surgery and those, who avoided resection of the large intestine, various clinical, laboratory and endoscopic parameters were compared. By results of logistic regression predictors of infliximab inefficiency were determined: presence of extensive ulcerative mucosal defects of the colon prior to the beginning of biological therapy (accuracy of colectomy prognosis 78%) and absence of clinical remission at the third injection of the drug (accuracy of colectomy prognosis of 69%).Conclusions. The investigated risk factors do not allow clear-cut prediction of relapse-free course of ulcerative colitis for one year of maintenance therapy by infliximab.https://www.gastro-j.ru/jour/article/view/1233ulcerative colitisinfliximabcolectomy
spellingShingle A. O. Golovenko
I. L. Khalif
O. V. Golovenko
V. V. Veselov
Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
ulcerative colitis
infliximab
colectomy
title Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
title_full Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
title_fullStr Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
title_full_unstemmed Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
title_short Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
title_sort predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
topic ulcerative colitis
infliximab
colectomy
url https://www.gastro-j.ru/jour/article/view/1233
work_keys_str_mv AT aogolovenko predictorsofinfliximabefficacyinpatientswithsevereattackofulcerativecolitis
AT ilkhalif predictorsofinfliximabefficacyinpatientswithsevereattackofulcerativecolitis
AT ovgolovenko predictorsofinfliximabefficacyinpatientswithsevereattackofulcerativecolitis
AT vvveselov predictorsofinfliximabefficacyinpatientswithsevereattackofulcerativecolitis